User Fee Negotiators Far Apart: Industry Seeks To Delay New Fee Levels Until FDA Improves Performance
This article was originally published in The Gray Sheet
Executive SummaryDevice industry reps say industry-paid FDA user fees should be reauthorized for only two years, not five, to allow ongoing changes to FDA's pre-market review programs to sink in before a more meaningful user fee package is passed.
You may also be interested in...
Hiring and retaining the staff, adjusting the internal culture at CDRH and rebuilding relationships with industry and other public stakeholders are among FDA’s top challenges in meeting the demands of the new device user fee program, according to CDRH Director Jeffrey Shuren.